what does solara active pharma do

Solara Active Pharma Sciences Limited is a pure-play API (Active Pharmaceutical Ingredient) manufacturing company that produces, processes, formulates, and distributes APIs for the pharmaceutical industry, with a focus on customer needs and value-based products.

what does solaraze gel do to the skin

Solaraze gel is a topical medication used to treat symptoms of hidradenitis suppurativa, such as pain, swelling, and inflammation in areas like the armpits, groin, and under the breasts.

what does solara mean in spanish

In Spanish, "Solara" means "sunny" or "solar."

what does solaraze gel do

Solaraze gel is a prescription topical gel containing clascibene that helps reduce inflammation and pain associated with hidradenitis suppurativa when applied to affected skin areas.

what does solaraze cream do

Solaraze cream is a topical formulation used to treat hidradenitis suppurativa by reducing redness, swelling, and discomfort in affected skin regions.

Solara Active Pharma Sciences Limited (SOLARA) Share Price Today — ₹572.55

Solara Active Pharma Sciences Limited (SOLARA) live stock price is ₹572.55. Listed on BSE. Sector: Healthcare. Industry: Pharmaceuticals & Biotechnology.

View Solara Active Pharma Sciences Limited stock charts, financial results, quarterly earnings, shareholding pattern, corporate actions, peer comparison and more on Black Bear Labs.

Compare with other stocks in the Healthcare sector.

Use our Stock CAGR Calculator to calculate returns for Solara Active Pharma Sciences Limited. Screen stocks with our Stock Screener.

Learn about key metrics: P/E Ratio, Market Cap, ROE, EPS.

SOLARA

BSE

Solara Active Pharma Sciences Limited

Healthcare· Pharmaceuticals & Biotechnology· INE624Z01016· Scrip: 541540

EN हिन्दी ગુજરાતી मराठी

₹572.55

▲ 5.40 (+0.00%)

2026-06-10

BSE

₹572.55

▲ 5.40

+0.00%

231 trading days · 1Y period

TODAY (BSE)

Open575.45

High586.95

Low563.00

Prev Close577.95

Volume46,523

Value₹2.7Cr

L: 563.00H: 586.95

Info

Face Value₹10

Listed2018-06-27

ISININE624Z01016

SeriesB

BSE Scrip541540

Key Metrics

1D

—

1W

—

1M

—

3M

—

6M

—

Valuation

P/E (TTM)—

P/E (Qtr Ann.)—

P/Sales—

Mkt Cap—

Growth (QoQ)

Revenue-13.44%

PAT+1.00%

EPS-20.08%

Profitability

EBITDA Margin19.7%

Net Margin2.7%

TTM EBITDA M.8.5%

TTM Net M.-19.2%

Dividend

Yield—

Latest DPS₹3

Payout Ratio147.8%

Growth-25.00%

TTM Revenue

₹1310 Cr

TTM EBITDA

₹112 Cr

TTM PAT

₹-252 Cr

TTM EPS

₹-69.56

Rev/Share

₹272.0

Quarterly Financials

Revenue

EBITDA

PAT

EPS

Quarter	Revenue	Expenses	EBITDA	PBT	PAT	EPS
2024-12-31	300 Cr	294 Cr	59 Cr	8 Cr	8 Cr	₹2.03
2024-09-30	347 Cr	339 Cr	62 Cr	8 Cr	8 Cr	₹2.54
2024-06-30	363 Cr	377 Cr	13 Cr	-12 Cr	-12 Cr	₹-3.20
2024-03-31	299 Cr	346 Cr	-22 Cr	-167 Cr	-255 Cr	₹-70.93
2023-12-31	249 Cr	462 Cr	-224 Cr	-275 Cr	-275 Cr	₹-76.49
2023-09-30	425 Cr	438 Cr	34 Cr	-17 Cr	-17 Cr	₹-4.77
2023-03-31	381 Cr	380 Cr	55 Cr	5 Cr	4 Cr	₹1.05
2022-12-31	395 Cr	401 Cr	52 Cr	1 Cr	0 Cr	₹0.12

Shareholding Pattern

CURRENT — 2026-05-15

Promoter42.0%

FII11.3%

DII3.8%

Public58.0%

PROMOTER HOLDING TREND

Corporate Actions

Ex-Date	Type	Purpose
2024-09-17	Other	Annual General Meeting
2024-05-15	Rights	Rights 1:3 @ Premium Rs 365/-
2023-09-08	Other	Annual General Meeting
2022-08-12	Other	Annual General Meeting
2021-08-18	Dividend	Annual General Meeting/Dividend - Rs 3 Per Share
2020-11-19	Dividend	Interim Dividend - Rs 4 Per Share
2020-07-28	Dividend	Annual General Meeting/Dividend - Rs 2 Per Share
2019-08-06	Dividend	Annual General Meeting/Dividend - Rs 5 Per Share
2018-09-18	Other	Annual General Meeting

Earnings Transcripts

Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings confere...

21 May 2026NSE45K chars

Read →

Solara Active Pharma Sciences Limited has intimated the Exchange about the Audio Recording of the Q4...

15 May 2026NSE2K chars

Read →

Solara Active Pharma Sciences Limited has informed the Exchange regarding the Earnings call Transcri...

11 Nov 2025NSE42K chars

Read →

Solara Active Pharma Sciences Limited has informed the Exchange about audio recording of Q2 FY26 ear...

5 Nov 2025NSE2K chars

Read →

Solara Active Pharma Sciences Limited has informed the Stock Exchange regarding the Earnings Call Tr...

29 Jul 2025NSE39K chars

Read →

Solara Active Pharma Sciences Limited has informed the Exchange about Earnings Call Transcript of An...

21 May 2025NSE34K chars

Read →

Price History

Date	Open	High	Low	Close	Volume
2026-06-10	574.00	584.60	563.30	572.80	3.51L
2026-06-03	542.05	545.45	534.05	538.85	82,577
2026-05-27	561.95	566.95	542.35	545.80	1.30L
2026-05-26	557.00	562.95	553.00	558.50	89,914
2026-05-25	546.25	559.45	543.75	554.25	1.62L
2026-05-22	565.60	565.60	543.10	548.10	1.62L
2026-05-21	580.00	580.00	558.55	564.25	1.83L
2026-05-20	581.95	606.40	558.40	573.65	3.85L
2026-05-19	559.85	593.00	554.90	582.65	2.95L
2026-05-18	574.55	578.80	546.65	561.35	4.66L
2026-05-15	514.10	598.50	502.00	579.90	40.14L
2026-05-14	501.35	513.10	492.20	507.70	79,606
2026-05-13	509.10	519.50	501.00	503.70	58,833
2026-05-12	526.00	531.75	504.00	508.60	79,295
2026-05-11	524.80	533.00	513.00	526.55	97,350
2026-05-08	517.45	547.70	513.65	525.35	3.12L
2026-05-07	512.80	529.00	512.80	514.85	93,949
2026-05-06	505.90	518.00	498.00	512.80	1.16L
2026-05-05	520.00	526.75	496.55	501.20	1.19L
2026-05-04	505.70	532.75	497.05	518.95	1.79L
2026-04-30	494.35	502.85	485.00	495.80	1.10L
2026-04-29	495.00	515.00	484.35	490.75	4.58L
2026-04-28	478.50	488.45	475.35	478.15	64,978
2026-04-27	480.00	489.70	476.60	483.30	50,504
2026-04-24	500.00	504.55	475.00	477.50	73,360
2026-04-23	489.00	518.00	488.05	498.65	1.61L
2026-04-22	483.05	493.00	482.15	489.00	36,289
2026-04-21	491.00	496.50	479.10	483.05	54,321
2026-04-20	499.10	503.00	486.10	491.60	53,949
2026-04-17	491.95	509.00	491.00	499.10	78,077

Frequently Asked Questions

About

Solara Active Pharma Sciences Limited, formerly part of Strides Shasun Ltd., focuses on developing and commercializing generic and specialty pharmaceutical products. Key offerings include generic formulations and potentially innovative drug delivery systems, though recent financials indicate a challenging position with negative profits and a low interest coverage ratio. Notably, the company was spun off through a demerger to form its own entity on the NSE, representing a distinct focus within India's pharmaceutical sector.